Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group.

Clinical and Experimental Immunology
J B MatthewsITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group

Abstract

Like many other complex human disorders of unknown aetiology, autoimmune-mediated type 1 diabetes may ultimately be controlled via a therapeutic approach that combines multiple agents, each with differing modes of action. The numerous advantages of such a strategy include the ability to minimize toxicities and realize synergies to enhance and prolong efficacy. The recognition that combinations might offer far-reaching benefits, at a time when few single agents have yet proved themselves in well-powered trials, represents a significant challenge to our ability to conceive and implement rational treatment designs. As a first step in this process, the Immune Tolerance Network, in collaboration with the Juvenile Diabetes Research Foundation, convened a Type 1 Diabetes Combination Therapy Assessment Group, the recommendations of which are discussed in this Perspective paper.

References

Mar 17, 1988·The New England Journal of Medicine·P F BougneresJ L Chaussain
Nov 30, 2000·Upsala Journal of Medical Sciences·F A KarlssonL Zhao
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Oct 4, 2002·The New England Journal of Medicine·Joep Killestein
Apr 30, 2003·Diabetes·Carla J GreenbaumUNKNOWN Immunology of Diabetes Society
Apr 1, 2005·The New England Journal of Medicine·Jacques Dantal, Jean-Paul Soulillou
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Apr 14, 2006·Endocrine, Metabolic & Immune Disorders Drug Targets·L M BekrisA Lernmark
Apr 22, 2006·The Journal of Clinical Investigation·Damien BressonMatthias von Herrath
Mar 14, 2007·Clinical and Experimental Immunology·T Staeva-VieiraM von Herrath
Mar 23, 2007·Annals of the New York Academy of Sciences·Bart O Roep
Oct 10, 2008·The New England Journal of Medicine·Johnny LudvigssonRosaura Casas
Dec 2, 2008·Clinical and Experimental Immunology·S L ThrowerM Peakman
Jan 9, 2009·Clinical and Experimental Immunology·A WillcoxN G Morgan
May 8, 2009·The Journal of Clinical Investigation·Matthias von Herrath, Andrew Chan
May 16, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Kevan C HeroldUNKNOWN Immune Tolerance Network ITN007AI Study Group
Aug 14, 2009·Diabetes·Kevan C HeroldUNKNOWN Type 1 Diabetes TrialNet Research Group
Nov 27, 2009·The New England Journal of Medicine·Mark D PescovitzUNKNOWN Type 1 Diabetes TrialNet Anti-CD20 Study Group
Jan 14, 2010·Diabetes Care·Peter A GottliebUNKNOWN Type 1 Diabetes TrialNet MMF/DZB Study Group
Jan 26, 2010·Nature Reviews. Immunology·Bart O Roep, Mark Peakman
Dec 1, 2010·Diabetes Care·Antoinette MoranUNKNOWN CFRD Consensus Conference Committee

❮ Previous
Next ❯

Citations

Jun 11, 2011·Current Diabetes Reports·George W BurkeAlberto Pugliese
Jul 31, 2012·Current Diabetes Reports·James A ThompsonTodd M Brusko
Jul 1, 2011·Lancet·Chantal Mathieu, Pieter Gillard
Jan 10, 2012·Nature Medicine·Lawrence SteinmanMark Peakman
Feb 3, 2012·The New England Journal of Medicine·Johnny LudvigssonSabine Baron
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Bart O Roep, Mark Peakman
Mar 7, 2012·Cold Spring Harbor Perspectives in Medicine·Lukas T JekerJeffrey A Bluestone
Feb 4, 2011·Science Translational Medicine·Damien Bresson, Matthias von Herrath
Aug 19, 2011·Science Translational Medicine·Mark A Atkinson
Jan 1, 2012·The Review of Diabetic Studies : RDS·Mario R Ehlers, Gerald T Nepom
Aug 2, 2013·International Journal of Biological Sciences·Yan-Ling WuWen Zhang
May 6, 2014·Disease Models & Mechanisms·Dawn E SmilekGerald T Nepom
Sep 20, 2011·Diabetes Management·Alberto PuglieseGeorge W Burke
Mar 7, 2014·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Anne JörnsSigurd Lenzen
Aug 17, 2011·Current Opinion in Endocrinology, Diabetes, and Obesity·Aaron W Michels, Matthias von Herrath
May 7, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ole J BjerrumHarrie C M Boonen
Aug 13, 2011·Seminars in Immunology·Manuela Battaglia, Maria-Grazia Roncarolo
Aug 20, 2011·Seminars in Immunology·Aaron W Michels, George S Eisenbarth
Nov 28, 2015·Journal of Pediatric Psychology·Jessica L Yarbro, Robyn Mehlenbeck
Nov 6, 2012·Clinical and Experimental Immunology·M Peakman
Nov 3, 2010·Immunology·Jeffrey BabadTeresa P DiLorenzo
Apr 12, 2013·Clinical and Experimental Immunology·M von HerrathB Roep
Jun 19, 2013·Pediatric Diabetes·Hilary R Thomas, Stephen E Gitelman
Jun 8, 2011·Clinical & Developmental Immunology·Slobodan CulinaRoberto Mallone
Jun 18, 2014·Diabetes Care·Jane L ChiangUNKNOWN Type 1 Diabetes Sourcebook Authors
Apr 16, 2016·Molecular Immunology·Sirong HeQuan Chen
Mar 17, 2015·Journal of Autoimmunity·Ghanashyam SarikondaMatthias von Herrath
Mar 1, 2014·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Shipra GuptaS Alice Long
Feb 18, 2015·Nature Reviews. Endocrinology·Paolo PozzilliRaffaella Buzzetti
Dec 17, 2014·The Journal of Clinical Investigation·Jay S Skyler
Dec 31, 2014·ELife·Yohko Kitagawa, Naganari Ohkura
Sep 2, 2010·Diabetes·Mark Peakman, Matthias von Herrath
Jan 5, 2011·Diabetes·Jay S Skyler, Camillo Ricordi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.